罗格列酮对冠心病合并2型糖尿病患者介入治疗后血管内皮功能的影响

Effect of rosiglitazone on vascular endothelial function in patients with diabetes and coronary artery disease after coronary angioplasty

目的观察罗格列酮对冠心病合并2型糖尿病患者介入术后血管内皮功能的影响。方法选择冠心病合并2型糖尿病行PCI患者102例,按照是否服用罗格列酮,随机分为治疗组(51例)和对照组(51例)。分别检测患者血液中NO、一氧化氮合酶(NOS)、内皮素1的含量变化,并观察患者的预后情况。结果与术前比较,2组患者在术后1、7 d时NO、NOS明显降低,内皮素1明显升高,差异有统计学意义(P<0.05,P<0.01);1个月时,对照组NO和NOS仍明显降低,差异有统计学意义(P<0.05)。与对照组比较,治疗组患者的冠状动脉事件发生率明显降低,差异有统计学意义(P<0.05)。结论罗格列酮可以通过改善血管内皮功能,并能减少冠心病合并2型糖尿病患者介入治疗后心血管事件的发生。

Objective To investigate the effect of rosiglitazone on vascular endothelial function in patients with type 2 diabetes and coronary artery disease（CAD） after PCI. Methods 102 patients with diabetes and CAD who had undergone PCI were randomized to therapy group（51 cases） and control group（51 cases） according to receiving or not receiving rosiglitazone. The changes in plas- ma NO,NOS and ET-1 were monitored. Results There were significant differences between ther- apy group and control group in the levels of NO,NOS and ET-1 at 24 hours and 7 days after PCI. There were also significant differences between therapy group and control group in the levels of NO and NOS at 1 month after PCI. Furthermore, the occurrence of coronary events was signifi- cantly decreased in the rosiglitazone group. Conclusion The results indicate that rosiglitazone may improve vascular endothelial function in patients with diabetes and CAD after PCI and de- crease coronary events.